Division of Respirology

Mark David Inman

B.Sc., M.Sc., Ph.D., M.D.

Professor, Division of Respirology, Department of Medicine



Awards and Distinctions

  • Harbinger Scholar in Respiratory Medicine (2001-present)
  • Departmental Career Award, Medicine (2000-2002)

Research Interests

Dr. Inman's research interests are in the mechanisms underlying airway dysfunction in asthma. Specific interests at this time involve exploring the mechanisms of airway wall remodeling as a result of chronic allergic inflammation, and how this results in altered airway function. He has developed a new model of chronic allergen challenge in mice, which produces airway remodeling and dysfunction similar to that observed in asthma.

Tools currently employed by the group include the measurement of airway physiology in small animals, quantification of pathologic changes in airway tissue using computerized morphometry techniques and quantification of the fibrotic/antifibrotic status within the airway using laser capture microdisection and real time RT-PCR.

Ongoing projects within the lab are aimed at understanding the mechanisms underlying pathologic and physiologic changes in this model as well as exploring avenues of pharmacological intervention. Funding for these projects is from both peer review agencies (CIHR and Ontario Thoracic Society) as well as from the pharmaceutical industry.


  • Canadian Institutes of Health Research: "Functional and structural responses to chronic allergic airway challenge in mice" (09/02 -10/05)
  • Ontario Thoracic Society: "The role of IL-13 and TH2 mediators in sustained allergen-induced airway hyperresposiveness" (07/03 - 06/04)
  • Asthma Society of Canada: "The effects of corticosteroid treatment in preventing/reversing sustained airway hyperresponsiveness and airway remodelling in mice exposed chronically to allergen"
  • Glaxo Smith Kline: "Combination therapy with corticosteroids and long acting ß2-agonists or anti-il-5 antibodies in a murine model of chronic allergic inflammation (2002)
  • Merck Frosst Canada: "Intervention with Montelukast in Murine Models of Chronic Allergic Inflammation" (2001, 2002)
  • Vasogen Incorporated: "Effects of Vasogen's immune modulation therapy in a TH2 dependent model of allergen-induced airway inflammation and dysfunction" (1999)

Selected Publications

  1. Ellis R, Leigh R, Southam D, O'Byrne PM and Inman MD. Morphornetric analysis of mouse airways after chronic allergen challenge. Lab Invest 83: 1285-1291, 2003.
  2. Kelly MM, Leigh R, Bonniaud P, Ellis R, Wattie J, Smith MJ, Martin G, Panju M, Inman MD and Gauldie J. Epithelial expression of profibrotic mediators in a model of allergen-induced airway remodeling. Am J Respir Cell Mol Biol 32: 99-107, 2005.
  3. Leigh R, Ellis R, Wattie J, Donaldson DD and Inman MD. Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am J Respir Crit Care Med 170: 851-856, 2004.
  4. Leigh R, Ellis R, Wattlie JN, Hirota JA, Matthaei KI, Foster PS, O'Byrne PM and Inman MD. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 169: 860-867, 2004.
  5. Leigh R, Southam DS, Ellis R, Wattie JN, Sehmi R, Wan Y and Inman MD. T-cell-mediated inflammation does not contribute to the maintenance of airway dysfunction in mice. J Appl Physiol 97: 2258-2265, 2004.
  6. ß2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med. Apr 15;165:1068-70, 2002.
  7. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. Eur.Resp.J. 109:789-93, 2002.
  8. Reversing effect of interferon- on TH2 responses after allergen challenge in sensitized interferon- deficient mice. Am.J.Resp.Crit.Care Med.15;166:451-6, 2002 .
  9. Different Mechanisms of airway hyperresponsiveness in mice following brief or chronic exposure to allergen. Am.J.Resp.Cell.Mol.Biol. 27(5):526-35, 2002
  10. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am.J.Resp.Crit.Care Med.166(9):1212-7, 2002.
  11. Do complex conditions require complex treatment? Am.J.Resp.Crit.Care Med.15;167:6, 2003.
  12. Morphornetric analysis of mouse airways after chronic allergen challenge. Lab.Invest. 83:1285-1291, 2003.